article Open AccessTop 10% cited
Polypharmacy as commonly defined is an indicator of limited value in the assessment of drug‐related problems
British Journal of Clinical Pharmacology · 2006 · Vol. 63(2) · pp. 187–195
Kirsten K. Viktil✉(Nanotherapeutics (United States))Hege Salvesen Blix(Nanotherapeutics (United States))Tron Anders Moger(University of Oslo)Aasmund Reikvam(Nanotherapeutics (United States))
Abstract
The number of DRPs per patient was linearly related to the number of drugs used on admission. To set a strict cut-off to identify polypharmacy and declare that using more than this number of drugs represents a potential risk for occurrence of DRPs, is of limited value when assessing DRPs in a clinical setting.
Pharmaceutical Practices and Patient OutcomesPharmaceutical studies and practicesHealth Systems, Economic Evaluations, Quality of LifePolypharmacyMedicineConfidence intervalDrugMedical recordEmergency medicineInternal medicinePediatricsPharmacology
MeSH terms
AgedAged, 80 and overDrug InteractionsEvaluation Studies as TopicFemaleHospitalizationHumansMaleMedication ErrorsMiddle AgedPolypharmacyDrug-Related Side Effects and Adverse Reactions
Funding
- Universitetet i Oslo
Citations
530
FWCI
5.42
field-weighted impact
References
39
Percentile
96%
vs. same field & year
Citations per year
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.